Form 4: Ionis Pharmaceuticals EVP C. Frank Bennett Reports Stock Purchase

C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, reports the purchase of 320 shares of common stock at $28.2115 per share.

Summary

• On February 28, 2025, C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals, acquired 320 shares of common stock through the company's employee stock purchase plan.
• The purchase price was $28.2115 per share.
• Following the transaction, Bennett directly owns 93,466 shares of Ionis Pharmaceuticals common stock.
• The acquired shares cannot be sold until August 28, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment. It's a routine insider transaction, indicating confidence but not necessarily a major positive catalyst.

Positives

• The purchase indicates confidence from a high-ranking executive in the company's future.

Industry Context

Insider transactions are closely watched as indicators of management's confidence in the company's prospects. Purchases are generally viewed more favorably than sales.

Stakeholder Impact

• The stock purchase by a key executive could have a slightly positive impact on shareholder sentiment.

Key Dates